Author: KCCure
Voice of Kidney Cancer – Words from Forrest
Forrest is a stage 3 kidney cancer survivor. He recently shared these thoughts in our clear cell kidney cancer patient community. His words not only showcase how many patients feel on a daily basis – they also explain why we believe that connecting with other patients and caregivers is such a crucial part of survivorship for kidney cancer patients. Thank you Forrest for inspiring others! W...
KCCure joins over 300 advocacy organizations urging Congress to protect Medicare part B
KCCure has joined with 339 other advocacy organizations urging Congress to halt implementation of a new pricing scheme that could negatively impact kidney cancer patients covered by Medicare. The “International Pricing Index” model, proposed by the Centers for Medicare & Medicaid Services (CMS) would affect 50 percent of physicians and hospitals serving Medicare Part B beneficiarie...
Treatment for Metastatic Kidney Cancer Edges Toward Approval
AVEO Oncology announced today that the Phase 3 TIVO-3 Trial of Tivozanib in metastatic kidney cancer has met its primary endpoint.
ESMO18 – Kidney Cancer Updates
KCCure reports live from #ESMO18 on kidney cancer updates and what we learned from the experts.
Lawing to Present on Rare Kidney Cancer at AACR Conference
Michael B. Lawing, Director of Outreach, KCCure has been selected to participate in the Scientist <-> Survivor Program at the 11th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved Nov. 2-5, 2018 in New Orleans, LA. The conference will address all levels of basic, population, clinical, and transdisciplinary research related ...
Voice of Kidney Cancer – Michael Robson
Today, the combination of Yervoy and Opdivo is approved in the U.S., Canada and Australia for treatment of first line metastatic kidney cancer, thanks in part to pioneers like kidney cancer patient Michael Robson who bravely participated in clinical trials. Most recently, Dr. Jim Allison was awarded the Nobel Prize in Medicine for his discovery of the mechanism that led to the development of these...
Letter to Kidney Cancer Journal and Response – Regarding Checkpoint Inhibitors in Non-Clear Cell RCC
Attached is a letter to the editor of the Kidney Cancer Journal and editorial response regarding the use of checkpoint inhibitors in non-clear cell RCC. We’re grateful to the editors of the journal for graciously providing this update for patients with rare types of kidney cancer. KCJ letter
Voice of Kidney Cancer – Viola’s Story
Hello, my friends. Like you, I am at war with Stage Four RCC. I’ve learned so much from everyone of you. This week marks the fifth anniversary of my diagnosis. Like many of you, it just seemed like it was one excruciating event after another. Since the worst of it seemed to be the decimation of my left femur, I endured many operations, learning to walk four times. Finally a wonderful surgery impla...
Voice of Kidney Cancer – Irene’s story
Prologue: This touching account of Irene’s brother Omar and his struggle with kidney cancer took place in the Philippines over six years ago. Shortly after his diagnosis, I was contacted by Irene and another sister Imee who lives in Singapore by e-mail; we remained in touch throughout the remainder of Omar’s life and occasionally thereafter. The family is still repaying loans for his treatment, an...
KCCure urges Congress and CMS to Reconsider Misguided Medicare Changes
KCCure joins 239 advocacy organizations asking Congress and CMS to reconsider changes allowing Medicare Advantage plans to implement a new policy that could negatively impact Medicare patients with kidney cancer.
Deadline Extension for Federal Kidney Cancer Research Program
This is to notify the research community of the recently extended deadline for the Fiscal Year 2018 (FY18) funding opportunities for the Department of Defense (DOD) Kidney Cancer Research Program (KCRP) being managed by the office of Congressionally Directed Medical Research Programs (CDMRP).